FFA
EVLO

Fairfield Financial Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Fairfield Financial Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-54
Closed -$1.73K – 334
2022
Q4 		$1.73K Hold
54
– – ﹤0.01% 278
2022
Q3 		$2.25K Hold
54
– – ﹤0.01% 285
2022
Q2 		$2.27K Hold
54
– – ﹤0.01% 269
2022
Q1 		$3.64K Buy
+54
New +$4.5K ﹤0.01% 270

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fairfield Financial Advisors's EVLO Position: Q1 2023 in Review

Fairfield Financial Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 54 shares — an estimated $1.73K sold.

Fairfield Financial Advisors first reported a position in EVLO in Q1 2022 and held it in 4 quarters. The position peaked at $3.64K in Q1 2022. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

  • Fairfield Financial Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 54 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $1.73K.
  • Fairfield Financial Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Fairfield Financial Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $3.64K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Fairfield Financial Advisors's 13F filing for Q1 2023, filed 4 Nov 2024.